Genetix Introduces the GSL-120 Slide Loader

Designed for Efficient, Automated Large Batch Cytogenetic Slide Processing

NEW MILTON, U.K.–Applied Imaging, a Genetix Group plc company (AIM:GTX), the cancer diagnostic and biopharmaceutical technologies group (, announces the launch of GSL-120 Slide Loader, a comprehensive solution for efficiently processing large batches of cytogenetic slides without the need for user intervention. The GSL-120 – which has already been shipped and installed at various customer locations – is specifically designed for integration with the Applied Imaging CytoVision system, providing a completely integrated cytogenetic imaging and analysis solution.

Unlike the traditional procedures that require technicians to manually search slides for the best cells, the GSL-120 fully automates this process, thereby providing significant productivity gains to cytogenetics laboratories. It is also the first slide loader to incorporate high quality image capture using an automated oiling system, an integrated bar code reader, as well as automatic data handling with trainable selection classifiers.

“Technological advancements are ushering in a new era in cytogenetics – and the GSL-120 is representative of our commitment and position at the forefront of this evolution,” states Dr. Julian Burke, Genetix Chief Scientific Officer. “Automated solutions for scanning and imaging vastly improve productivity, digitized analysis is more accurate and consistent than traditional microscope examination and electronic, digital data capture enables connectivity without geographic boundaries.”

About Genetix

Genetix ( delivers the competitive edge in cell identification and selection from discovery to diagnosis. Genetix technologies are bringing new efficiencies to biopharmaceutical and biomarker research from target discovery through to clinical diagnosis. We continually deliver technological breakthroughs to increase our customers’ productivity and success. Genetix customer base includes many of the world’s leading biopharmaceutical, cytogenetic and cancer pathology groups.

Genetix is quoted on the AIM (symbol: GTX) and is based in New Milton, Hampshire, UK with offices in the US, UK, Germany and Japan.

< | >